Antinuclear Antibodies Are Common and Linked to Poor Response to Omalizumab Treatment in Patients With CSU

Allergy: European Journal of Allergy and Clinical Immunology - United Kingdom
doi 10.1111/all.14033
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Omalizumab in Patients With Antihistamine-Resistant CSU

British Journal of Dermatology
DermatologyMedicine
2019English

Are Currently Available Biomarkers Useful to Discriminate CSU Patients Not Controlled by Low Dose Omalizumab Maintenance Therapy?

European Annals of Allergy and Clinical Immunology
AllergyImmunology
2020English

Antinuclear Antibodies in Patients With Raynaud's Phenomenon: Clinical Significance of Anticentromere Antibodies.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1982English

Antinuclear Antibodies During Procainamide Treatment and Drug Acetylation.

BMJ
1975English

Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia

Frontiers in Pediatrics
Child HealthPediatricsPerinatology
2020English

Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Response to ‘Antinuclear Antibodies by Indirect Immunofluorescence and Solid Phase Assays’ by Bossuyt Et Al

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2019English

THU0707 Analysis of Antinuclear Antibodies in Breast Cancer Patients

2018English

Omalizumab Treatment in Patients With Chronic Spontaneous Urticaria

Bőrgyógyászati és Venerológiai Szemle
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy